Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.41 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.41 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
| ▸ | PNMT | P11086 | 1/20 | 0.35 |
| ▸ | CD44 | P16070 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD1 | P21728 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | DRD5 | P21918 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31324112 | 1.00 | MAPT (0.47) | MAPTTSHRNPC1MAPK13MAPK12 | |
| SCHEMBL11813586 | 0.94 | TSHR (0.48) | MAPTTSHRNPC1MAPK13MAPK12 | |
| SCHEMBL29603326 | 0.86 | HTR2C (0.48) | MAPTTSHRNPC1MAPK13MAPK12 | |
| SCHEMBL209619 | 0.86 | HTR2C (0.48) | MAPTTSHRNPC1MAPK13MAPK12 | |
| Hydrochloric Acid SCHEMBL28169336 | 0.84 | HTR2C (0.46) | MAPTTSHRNPC1MAPK13MAPK12 | |
| SCHEMBL31634869 | 0.81 | MAPT (0.46) | MAPTTSHRNPC1MAPK13MAPK12 | |
| SCHEMBL27392334 | 0.77 | MAPT (0.50) | MAPTTSHRNPC1MAPK13MAPK12 | |
| SCHEMBL18172 | 0.77 | MAPT (0.50) | MAPTTSHRNPC1MAPK13MAPK12 | |
| SCHEMBL29370549 | 0.77 | MAPT (0.50) | MAPTTSHRNPC1MAPK13MAPK12 | |
| Methane SCHEMBL11211553 | 0.76 | MAPT (0.48) | MAPTTSHRNPC1MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 686 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250338712-A1 | LIGHT-EMITTING DEVICE INCLUDING ORGANOMETALLIC COMPOUND, ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE, AND THE ORGANOMETALLIC COMPOUND | SAMSUNG DISPLAY CO LTD (KR) | 2025-10-30 | — | — | US | claimed |
| CN-118436801-A | PROTAC antibody conjugates and methods of use thereof | 豪夫迈·罗氏有限公司 | 2024-08-06 | — | — | CN | claimed |
| US-20230386615-A1 | BINDING SITE IN TYPE 1 RYANODINE RECEPTOR | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2023-11-30 | — | — | US | claimed |
| US-20230368862-A1 | BINDING SITE IN TYPE 2 RYANODINE RECEPTOR | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2023-11-16 | — | — | US | claimed |
| CN-116768858-A | Chimeric compounds having KRAS-SOS1 inhibitory or degrading activity and uses thereof | 杭州中美华东制药有限公司 | 2023-09-19 | — | — | CN | claimed |
| CN-114621231-A | Chimeric compound with targeted degradation/inhibition activity and preparation method and application thereof | 杭州中美华东制药有限公司 | 2022-06-14 | — | — | CN | claimed |
| CN-113861128-A | Polymerizable compound and optically anisotropic body | 江苏创拓新材料有限公司 | 2021-12-31 | — | — | CN | claimed |
| US-20210379087-A1 | COMPOSITIONS FOR THE ELIMINATION OF SENESCENT CELLS | MEDIZINISCHE UNIVERSITÄT WIEN (AT) | 2021-12-09 | — | — | US | claimed |
| CN-113347969-A | Composition for eliminating senescent cells | 维也纳自然资源与生命科学大学 | 2021-09-03 | — | — | CN | claimed |
| CN-108112251-B | NRF2 modulators | 葛兰素史克知识产权发展有限公司 | 2021-03-05 | — | — | CN | claimed |
| WO-2008141189-A1 | GHRELIN MODULATING COMPOUNDS AND COMBINATIONS THEREOF | ELIXIR PHARMACEUTICALS, INC. (US) | 2008-11-20 | — | — | WO | claimed |
| EP-1276462-B1 | SUSTAINED RELEASE DRUG DELIVERY DEVICES, METHODS OF USE, AND METHODS OF MANUFACTURING THEREOF | PSIVIDA INC (US) | 2008-09-24 | — | — | EP | claimed |
| EP-1924562-A2 | PYRAZOLONE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-28 | — | — | EP | claimed |
| WO-2007025880-A2 | PYRAZOLONE DERIVATIVES AS 11-BETA HSD1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-08 | — | — | WO | claimed |
| US-20070049574-A1 | New pyrazolones as 11b-HSD1 inhibitors for diabetes | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-01 | — | — | US | claimed |
| US-20050123906-A1 | Protein modulation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-06-09 | — | — | US | claimed |
| EP-1027042-A4 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL MYERS SQUIBB CO (US) | 2004-08-18 | — | — | EP | claimed |
| US-6110486-A | ADMINISTERING AN EFFECTIVE AMOUNT OF A DRUG TO A MAMMAL IN NEED OF SAME, BY SPRAYING THE ORAL MUCOSA WITH A BUCCAL SPRAY FORMULATION DISPENSING FROM A PUMP SPRAY FOR TRANSMUCOSAL ADMINSTERATION DISSOLVED IN A POLAR SOLVENT | FLEMINGTON PHARMACEUTICALS CO. (US) | 2000-08-29 | — | — | US | claimed |
| EP-1027042-A1 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-08-16 | — | — | EP | claimed |
| WO-1999018951-A1 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-04-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049574-A1 | New pyrazolones as 11b-HSD1 inhibitors for diabetes | HSD11B1, HSD17B1, HSD17B7 | MAPT 3706/4885TSHR 1762/4885NPC1 574/4885 |
| US-20230368862-A1 | BINDING SITE IN TYPE 2 RYANODINE RECEPTOR | RYR2, RYR1, ATP2A2 | MAPT 3523/4885TSHR 1286/4885NPC1 2413/4885 |
| US-20050123906-A1 | Protein modulation | MAVS, PPP4R3A, PPP1R10 | MAPT 919/4885TSHR 4532/4885NPC1 2184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.